Introduction {#Sec1}
============

When blood vessels are damaged, circulating platelets come into contact with activating stimuli that trigger aggregation and enable them to form a hemostatic plug. This process is subject to both positive and negative feedback to ensure that platelets respond appropriately to damage and do not form thrombi that totally occlude the vessel. It is believed that dysregulation of negative feedback mechanisms contributes to increased risk of thrombosis associated with some diseases. Despite this association with thrombosis, platelet-derived negative regulators of platelet activation are relatively poorly understood in comparison to mediators of platelet activation. However, it is becoming increasingly apparent that the mechanisms by which platelets restrain activation are diverse and of equal complexity to those that mediate positive signaling. Some regulators, such as RASA3 and JAM-A, act as gatekeepers that must be deactivated before platelet activation can occur. In contrast, regulators that contain ITIMs, such as PECAM-1, are activated following stimulation and mediate negative regulation via phosphatases that restrain activation. Wnt3a and ESAM are thought to directly limit platelet-platelet adhesion by blocking activation of the fibrinogen receptor, integrin α~IIB~β~3~. The various isoforms of PKC expressed by platelets elicit a diverse and complex array of inhibitory effects including receptor desensitisation. Many platelet derived inhibitors have been identified but not yet fully characterized and so questions remain regarding the details of their roles in the regulation of platelet activity. In this chapter we have described platelet-derived inhibitors of platelet function that are secreted by or expressed within platelets themselves to provide inhibition or negative regulation to the processes that underpin activation (Table [1](#Tab1){ref-type="table"}).Table 1Platelet-derived inhibitors of platelet activation**Immunoreceptor tyrosine-based inhibitory motif containing receptors (ITIMs)**PECAM-1CEACAM1/2G6b-BPIRB/LILRB**Intracellular nuclear receptors**PPARs (PPARα, PPARβ/δ and PPARγ)LXRRXRGR**Negative regulators of small GTPases and integrin α** ~**IIb**~ **β** ~**3**~RASA3JAM-AESAMWnt3aNeuropilin-1 plexin A complex**Cyclic nucleotide signaling**cAMP and PKAPlatelet-derived NO and PKG**Other mechanisms**PhosphatasesReceptor desensitisationProtein kinase C isoforms (*PKCδ and PKCθ*)Platelet-derived inhibitors of platelet function that are secreted or expressed by within platelets that provide inhibition or negative regulation to the processes that underpin activation

ITIM Signaling {#Sec2}
==============

Immunoreceptor tyrosine-based inhibitory motif (ITIM) containing receptors are capable, following ligand binding, of triggering cell signaling mechanisms that counteract activation processes. The ITIM consensus sequence L/I/V/S-x-Y-x-x-L/V usually found in the cytoplasmic tail has been identified in several proteins that are expressed in platelets, including PECAM-1, CEACAM, G6b-B, and LILRB2/PIRB which are associated with the negative regulation of platelet activation (Wu and Lian [@CR158]; Cicmil et al. [@CR23]; Jones et al. [@CR57]; Wong et al. [@CR157]; Alshahrani et al. [@CR6]; Yip et al. [@CR160]; Newland et al. [@CR101]; Mori et al. [@CR93]; Coxon et al. [@CR26]). When ITIM-bearing receptors bind their ligand, the receptors cluster and src family kinases phosphorylate the tyrosine residues in the ITIM motif. The phosphorylated ITIM is then able to recruit negative regulators including phosphatases such as SHP1/SHP2 (Kharitonenkov et al. [@CR65]) and SHIP1/SHIP2 (Bruhns et al. [@CR12]). The recruited phosphatases are localised within close proximity to their substrates, which allows them to inactivate molecules involved in activatory cell signaling including tyrosine kinases and phosphatidylinositol 3-kinase (PI3K) (Fig. [1](#Fig1){ref-type="fig"}). ITIMs were initially considered to be the 'off switch' that counteracts the positive signaling initiated by ITAM (Immunoreceptor tyrosine-based activation motif, consensus sequence Yxx(L/I)x~6--12~Yxx(L/I)) containing receptors such as the GPVI (glycoprotein VI) receptor complex. However, studies have now identified negative regulation of GPCR signaling by PECAM-1 and G6b-B that are independent of ITAM signaling pathways (Newland et al. [@CR101]; Jones et al. [@CR58]) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1ITIM signaling. When ITIM-bearing receptors bind their ligand they cluster and the ITIM domains are phosphorylated. The phosphorylated ITIM domains recruit phosphatases through their SH2 domains, bringing them into close proximity with their substrates. The phosphatases SHP1/2 and SHIP1/2 dephosphorylate PI3K, LAT and PLCγ2 and other molecules in the signaling pathways evoked by ITAM containing/linked receptors, such as GPVI, causing inactivation and contributing to negative regulation. The phosphatases recruited by ITIMs are also able to negatively regulate PI3K downstream of GPCRs, contributing negative regulation to non-ITAM signaling pathways

PECAM-1 {#Sec3}
-------

Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a 130 kDa member of the immunoglobulin superfamily that is expressed on several haematopoietic cells including platelets, monocytes, neutrophils, some types of T cells and endothelial cells and is associated with several biological processes including negative regulation of platelet activation (Newman [@CR102]). PECAM-1 contains a 574 amino acid extracellular domain that is composed of 6 Ig-like domains and mediates homophilic interactions with other PECAM-1 molecules. It also contains a short 19 amino acid single transmembrane spanning domain and a 118 amino acid cytoplasmic domain that includes the ITIM (Sun et al. [@CR136]; Newton et al. [@CR104]; Goyert et al. [@CR44]; Lyons et al. [@CR71]). Expression levels of PECAM-1 are variable with copy numbers ranging between 5,000 and 20,000 present at the cell surface per platelet (Jones et al. [@CR58]). PECAM-1 is present in platelet α-granules, resulting in an increase in cell surface expression following platelet activation and granule secretion (Hidari et al. [@CR53]; Wu and Lian [@CR158]; Metzelaar et al. [@CR82]; Jones et al. [@CR58]). PECAM-1 is believed to be activated by homomeric clustering (Thai le et al. [@CR142]) but interactions with other receptors have also been reported (Buckley et al. [@CR13]). Clustering of PECAM-1 to ITAM containing receptors or ligation of PECAM-1 using anti-PECAM-1 antibodies or recombinant human PECAM-1 immunoglobulin chimeras has been shown to inhibit GPVI, GPIb and GPCR-stimulated platelet aggregation. Activation of PECAM-1 has broad effects on signal transduction, including reduced total tyrosine phosphorylation, inositol tris-phosphate production, Ca^2+^ mobilisation and granule secretion which underpins a reduction in thrombus formation (Cicmil et al. [@CR24]; Jones et al. [@CR57], [@CR58]; Thai et al. [@CR143]; Rathore et al. [@CR114]). PECAM-1^−/−^ platelets exhibit hyperreactivity when stimulated with low concentrations of collagen and CRP (collagen related peptide) but not thrombin, ADP or PAR receptor agonists. Studies that have measured laser-induced thrombus formation in cremaster muscle arterioles in vivo using mice deficient in PECAM-1 indicate an inhibitory role for PECAM-1 in the regulation of thrombus formation, as increased thrombus size and stability is observed (Falati et al. [@CR34]).

PECAM-1 is regulated by phosphorylation of its cytoplasmic tail at the tyrosine residues Y663 and Y686 within the ITIM and ITSM (immunoreceptor tyrosine-based switch motif) motifs. PECAM-1 is constitutively phosphorylated at low levels in resting platelets and phosphorylation is increased following anti-PECAM-1 antibody induced crosslinking, but also in response to several platelet agonists including collagen, convulxin, thrombin and GPIb agonists suggesting that PECAM-1 provides a negative feedback mechanism to control the level of platelet activation and thrombus formation (Jackson et al. [@CR55]; Modderman et al. [@CR84]; Cicmil et al. [@CR23]; Jones et al. [@CR57]; Rathore et al. [@CR114]). Phosphorylation of PECAM-1 at an ITIM is mediated by activation of Src family kinases and Fyn, Lyn, Src, Yes and Hck have all been shown to coimmunoprecipitate with PECAM-1 (Cao et al. [@CR17]; Cicmil et al. [@CR23]). Phosphorylated ITIMs provide a binding and activation platform for SH2 domain containing proteins, including phosphatases SHP1 and SHP2, SHIP1 and PP2A (Pumphrey et al. [@CR110]; Relou et al. [@CR116]; Henshall et al. [@CR52]) that are associated with the negative regulation of platelet activity. Following activation of GPVI signaling, PI3K associates with the LAT signalosome which is located in lipid rafts that are enriched with the phosphoinositide substrates of PI3K. In contrast to LAT, the majority of PECAM-1 molecules are excluded from lipid rafts. Following crosslinking of PECAM-1, SHP2 is recruited to PECAM-1 and associates with PI3K, relocalising PI3K away from lipid rafts and the LAT signalosome, preventing association with and activation of PI3K (Moraes et al. [@CR89]). Most recently the mechanism by which PECAM-1 negatively regulates responses to non-GPVI agonists such as thrombin and VWF has also been described (Jones et al. [@CR60]). PECAM-1 inhibits fibrinogen binding and secretion stimulated by thrombin but not PAR1 and PAR4 activating peptides, which suggests that PECAM-1 has a role in regulating GPIbα, a receptor that recruits thrombin to the platelet plasma membrane facilitating stimulation of PARs (Jones et al. [@CR59]). PECAM-1 was found to mediate the internalisation of GPIbα in platelets through dual AKT/glycogen synthase kinase-3/dynamin-dependent and α~IIb~β~3~-dependent mechanisms.

A study looking at the expression patterns of PECAM-1 in platelets has identified that expression levels of PECAM-1 are variable within the human population with approximately 5,000--20,000 copies estimated to be present at the cell surface. Analysis of the relationship between receptor expression levels and platelet responsiveness to platelet agonists revealed an inverse relationship between levels of PECAM-1 expression and platelet response to stimulation by CRP and ADP (Jones et al. [@CR58]). Although the association is described as modest accounting for 6--10 % of total variability in responses, this was at a similar level of magnitude to that observed for the positive correlation of GPVI or α~IIb~β~3~ expression levels with platelet responsiveness.

Despite the overall negative role for PECAM-1 in the regulation of platelet activity, PECAM-1 signaling in other cell types is associated with the regulation of integrin function, whereby crosslinking of PECAM-1 enhances adhesion mediated by integrins (Tanaka et al. [@CR140]; Piali et al. [@CR107]; Leavesley et al. [@CR68]; Berman et al. [@CR10]; Varon et al. [@CR150]; Chiba et al. [@CR20]; Zhao and Newman [@CR161]). Studies in human platelets have shown that antibody crosslinking of PECAM-1 enhances adhesion and spreading on fibrinogen (Zhao and Newman [@CR161]) indicating a positive role for PECAM-1 in the regulation of integrin α~IIb~β~3~. Mouse platelets deficient in PECAM-1 show impaired spreading and adhesion on fibrinogen, clot retraction and phosphorylation of focal adhesion kinase, suggesting a defect in integrin α~IIb~β~3~ outside-in signaling (Wee and Jackson [@CR155]). It has been hypothesised that a dual role for PECAM-1 could therefore exist, in which it initially functions to suppress platelet activation but once platelets are strongly activated, PECAM-1 positively regulates functions mediated by integrin outside-in signaling (Jones et al. [@CR59]).

High plasma cholesterol levels significantly increase an individual's risk of atherosclerosis, coronary heart disease, heart attacks and stroke. Statins are widely prescribed as cholesterol lowering drugs and have been shown to reduce platelet activation. It has been described that one possible mechanism by which statins inhibit platelet function is through the activation and regulation of PECAM-1 (Moraes et al. [@CR92]). Treatment of platelets with simvastatin results in increased PECAM-1 phosphorylation and recruitment of SHP2 to the ITIM which are essential for the negative function of PECAM-1. In further support of statins working through PECAM-1, PECAM-1 deficient mouse platelets showed reduced sensitivity to statins compared to WT controls indicating that statins exert their effects via PECAM-1.

CEACAM1 and CEACAM2 {#Sec4}
-------------------

Carcinoembryonic antigen (CEA)-related cell adhesion molecules, CEACAM1 and CEACAM2 are ITIM containing membrane receptors that are expressed in both human and mouse platelets. CEACAM1 and 2 both contain extracellular glycosylated Ig-domains (four in CEACAM1 and two in CEACAM2), a transmembrane domain and a long cytoplasmic tail that contains the ITIM which is almost identical between the two proteins (Salaheldeen et al. [@CR120]). CEACAM1 is activated following clustering via a homophilic interaction. The endogenous ligand of CEACAM2 has not yet been identified but can be activated by the murine coronavirus mouse hepatitis virus spike glycoprotein(s) (Robitaille et al. [@CR117]). Studies using other cell types including T-cells and epithelial cells (Nagaishi et al. [@CR96]) have shown that CEACAM1 and CEACAM2 use their ITIMs to recruit SHP1 and, to a lesser degree, SHP2 which can then initiate negative regulation of positive signaling pathways (Beauchemin et al. [@CR9]).

Mice deficient in either CEACAM1 or CEACAM-2 show increased adhesion to fibrillar collagen and increased aggregation and secretion evoked by GPVI which indicates a role for both receptors in the negative regulation of GPVI signaling and platelet responses (Wong et al. [@CR157]; Alshahrani et al. [@CR6]). CEACAM2 deficient platelets have also been shown to exhibit increased platelet responses to CLEC-2 agonist Rhodocytin. Platelets deficient in either CEACAM1 or CEACAM2 show increased tyrosine phosphorylation of Syk and PLCγ2 following stimulation by CRP and also Rhodocytin in CEACAM2^−/−^ platelets. Platelets from mice deficient in either CEACAM1 or CEACAM2 display increased thrombus growth in vitro and in vivo suggesting that CEACAM1 and 2, like PECAM-1, are negative regulators of platelet GPVI signaling. Also similar to that observed with PECAM-1, it has been recently described that CEACAM1^−/−^ platelets show reduced signaling and activation through α~IIb~β~3~ suggesting an alternative, positive regulatory mechanism for CEACAM1 in platelets (Yip et al. [@CR160]). The role of CEACAM2 in the regulation of integrin α~IIb~β~3~ is as yet unknown .

G6b-B {#Sec5}
-----

The transmembrane protein G6b was identified through both proteomics and gene expression studies (Macaulay et al. [@CR73]; Senis et al. [@CR125]) and the G6b-B variant was confirmed to be present in platelets (Senis et al. [@CR125]). G6b-B contains an extracellular domain consisting of 125 amino acids and a cytoplasmic tail that contains two ITIM sequences. The endogenous ligand of G6b-B has not yet been identified, but G6b-B has been shown to be constitutively phosphorylated in resting platelets, and this increases following stimulation with GPVI specific agonist CRP or thrombin (Senis et al. [@CR125]). Treatment of cells expressing G6b-B with pervanadate to inhibit phosphatases enhances tyrosine phosphorylation of G6b-B and the recruitment of SHP1 and SHP2 (de Vet et al. [@CR30]; Coxon et al. [@CR26]), thereby suggesting that G6b-B works via a similar mechanism to other ITIM containing proteins to inhibit platelets. Interestingly, studies using the DT40 cell line show that inhibition of GPVI signaling following G6b-B expression is retained in the absence of both SHP1 and SHP2, and is also retained in the absence of SHIP suggesting redundancy between these phosphatases or the involvement of other inhibitory molecules and mechanisms of action (Mori et al. [@CR93]). Recent studies have identified that G6b-B is capable of interacting with several key signaling molecules, including Csk, Src, Fyn, Syk, PLCγ2 and PI3K, and it has been suggested that G6b-B may mediate its inhibitory effects on signaling and platelet activity by redistributing signaling molecules away from their substrates (Coxon et al. [@CR26]). Further evidence of a negative regulatory role for G6b-B in platelets was found by using a crosslinking antibody for G6b-B which caused inhibition of platelet aggregation to CRP, and ADP. No alteration in ADP-stimulated Ca^2+^ signaling was observed suggesting that G6b-B acts downstream of Ca^2+^ release. This suggests that G6b-B may act via an alternative inhibitory mechanism to that observed downstream of other ITIM containing receptors such as PECAM and CEACAM, where G6b-B is capable of inhibiting signaling events downstream of mobilisation of intracellular Ca^2+^ (Newland et al. [@CR101]). However, G6b-B deficient mice do not show platelet hyperreactivity, although this is likely to be attributed to an increase in GPVI receptor shedding, that is observed as a result of enhanced metalloproteinase production in the megakaryocytes of these mice (Mazharian et al. [@CR78]). This indicates an important role for G6b-B in megakaryocytes but the physiological role of G6b-B in platelets remains unclear (Mazharian et al. [@CR78]).

PIRB/LILRB {#Sec6}
----------

The leukocyte immunoglobulin like receptors (LILRs) include two subfamilies, LILRA and LILRB, whilst the LILRA proteins contain an ITAM domain, the LILRB family members are characterised as containing an ITIM. Human platelets express LILRB2 and mouse platelets express its homolog PIRB which contains four cytoplasmic ITIMs (Takai [@CR138]). Platelets have also been found to express the PIRB ligand ANGPTL2, which is found in alpha granules, and may suggest that autocrine self-negative regulation of platelets via PIRB/LILRB2 following their activation may occur (Zheng et al. [@CR162]; Fan et al. [@CR35]). Recent studies have identified that treatment of platelets with purified ANGPTL2 results in an inhibition of their activation to several agonists including CRP, ADP and thrombin while adhesion and spreading on fibrinogen is also inhibited (Fan et al. [@CR35]). PIRB-TM mutant mice, which are unable to mediate intracellular signaling through this receptor, have a hyper-reactive platelet phenotype with increased aggregation evoked by CRP, increased spreading on fibrinogen and increased clot retraction. Key GPVI signaling events following activation by CRP including phosphorylation of LAT, SLP-76 and PLCγ2 are inhibited following ANGPTL2 treatment and increased in PIRB-TM mutants. During adhesion to fibrinogen, phosphorylation of FAK and β3 is also enhanced in PIRB-TM mouse platelets. PIRB dependent inhibition of GPVI and integrin α~IIb~β~3~ signaling has been linked to the recruitment of SHP1 and SHP2 phosphatases, as both are recruited to PIRB and are phosphorylated following treatment with ANGPTL2 but their recruitment and phosphorylation is reduced in PIRB-TM expressing mice (Fan et al. [@CR35]).

Intracellular Nuclear Receptors {#Sec7}
===============================

Several intracellular nuclear receptors have been identified and characterised in human platelets including the peroxisome proliferator activating receptors (PPAR)s, PPARα, PPARβ/δ and PPARγ, the retinoid X receptor (RXR), liver X receptor (LXR), farnesoid X receptor (FXR) and glucocorticoid receptor (GR) (Moraes et al. [@CR86], [@CR88], [@CR91]; Spyridon et al. [@CR130]; Ali et al. [@CR2]) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Intracellular nuclear receptor signaling. Several intracellular nuclear receptors have been identified and characterised in human platelets including the peroxisome proliferator activating receptors (PPAR)s, PPARα, PPARβ/δ and PPARγ, the retinoid X receptor (RXR), liver X receptor (LXR), farnesoid X receptor (FXR) and glucocorticoid receptor (GR). The nuclear receptors are believed to negatively regulate platelet activity through various mechanisms following activation by their ligands, although these mechanisms are not well characterised. Both PPARα and PPARβ/δ are thought to negatively regulate platelet function through regulation of cAMP levels, whilst PPARγ and LXR receptors interact with and inhibit components of early GPVI signaling. In contrast RXR and GR appear to inhibit Gq signaling events. *Grey lines* represent platelet agonist signaling and *black arrows* represent the pathways or proteins that are modulated by nuclear receptor agonists in platelets

Peroxisome Proliferator Activated Receptors {#Sec8}
-------------------------------------------

PPARs represent three nuclear receptor isoforms, PPARα, PPARβ and PPARγ (Berry et al. [@CR11]) which are involved in cell development, differentiation, cholesterol and fatty acid metabolism and glucose homeostasis (O'Brien et al. [@CR105]; Barak et al. [@CR8]; Kersten et al. [@CR64]). All three isoforms of PPAR, upon binding to their ligands, are capable of heterodimerising with RXR, another nuclear receptor and all have been identified to have acute non-genomic negative regulatory effects in human platelets.

Treatment of platelets with ligands for PPARα such as fenofibrate and statins was found to increase intracellular levels of cAMP resulting in inhibition of ADP-stimulated platelet activation. Fenofibrate was also found to inhibit platelet activation and increase bleeding time in WT mice but not mice deficient in PPARα^−/−^ (Ali et al. [@CR4]). Following activation by fenofibrate, PPARα was found to associate with PKCα a key positive mediator of platelet activation, and it is thought that this interaction may in part contribute to the negative regulation of platelet activation that is observed following treatment with PPARα ligands.

PPARβ/δ has been shown to decrease plaque formation and attenuate the progression of atherosclerosis (Lee et al. [@CR69]). Studies using synthetic agonists for PPARβ/δ, GW0742 and L-165041 have identified inhibitory actions for PPARβ/δ ligands on the mobilisation of intracellular Ca^2+^ and platelet aggregation following stimulation by ADP and other platelet agonists (Ali et al. [@CR3]). PGI~2~ a key inhibitory mediator of platelet function is also a ligand for PPARβ/δ and some of its inhibitory effects on platelet activity could be mediated through PPARβ/δ (Forman et al. [@CR36]). As with PPARα, treatment of platelets with agonists of PPARβ/δ results in an increase in cAMP levels and PKCα has been identified as a potential binding partner of the receptor and a potential mechanism by which PPARβ/δ may regulate platelet reactivity (Ali et al. [@CR5]).

Agonists of PPARγ, the thiazolidinediones are currently in use for the treatment of type 2 diabetes mellitus and have been observed clinically to have cardio-protective properties and reduce the risk of myocardial infarction (Dormandy et al. [@CR31]; Sauer et al. [@CR121]). The emerging role of PPARγ agonists as negative regulators of platelet function may provide a mechanistic basis for this observation. A clinical study that measured platelet function in patients with coronary heart disease treated with rosiglitazone reported long-term anti-platelet effects with down-regulation of P-selectin exposure and granule secretion in treated patients (Sidhu et al. [@CR128]). Treatment of platelets ex vivo with the endogenous agonist of PPARγ, 15dPGJ~2~ or the synthetic agonist rosiglitazone results in reduced platelet responses including granule secretion and thromboxane B~2~ (T~X~B~2~) synthesis in response to thrombin or ADP (Akbiyik et al. [@CR1])~.~ Agonists of PPARγ have also been shown to suppress platelet activation stimulated by GPVI agonists, with platelet aggregation, granule secretion and mobilisation of intracellular Ca^2+^ inhibited following treatment with 15dPGJ~2~ (Moraes et al. [@CR91]). Treatment with PPARγ agonists results in reduced thrombus formation in vitro and in vivo (Moraes et al. [@CR91]; Li et al. [@CR70]).

Additionally statins that are routinely prescribed as cholesterol lowering drugs have also been shown to activate PPARs (Ali et al. [@CR4]). Treatment of human whole blood with the statins, pravastatin, fluvastatin and simvastatin all resulted in a reduction in platelet aggregation to ADP. This decrease in platelet activity was attributed to a PPAR mediated increase in cAMP levels.

RXR {#Sec9}
---

Human platelets and megakaryocytes express RXRα and RXRβ (Moraes et al. [@CR88]). Treatment of platelets with the endogenous agonist of RXR, 9-cis-retinoic acid or the synthetic agonist, methoprene acid, results in an inhibition of Gq protein coupled induced platelet aggregation that is stimulated by ADP and thromboxane A2 (TxA2). It is thought RXR regulates GPCR mediated platelet activation by binding to Gq in a ligand-dependent manner inhibiting Gq induced rac activation and intracellular Ca^2+^ release (Moraes et al. [@CR88]).

LXR {#Sec10}
---

The LXRα and LXRβ isoforms of LXR are implicated in the regulation of fatty acid, cholesterol and glucose homeostasis (Viennois et al. [@CR151], [@CR152]) and agonists for LXR have been described to have anti-inflammatory effects and be atheroprotective (Joseph et al. [@CR61]; Tangirala et al. [@CR141]). LXRβ has been identified as the isoform present in platelets (Spyridon et al. [@CR130]), and endogenous ligands for the LXR receptors include oxysterols (oxygenated derivatives of cholesterol) and several synthetic agonists including GW3965 and T0901317 also exist (Gabbi et al. [@CR37]; Wójcicka et al. [@CR156]). Treatment of platelets with synthetic agonist GW3965 results in inhibition of platelet activation, including aggregation, secretion and integrin activation stimulated by collagen, CRP or thrombin. GW3965-treated mice form smaller, less stable thrombi following laser injury of the cremaster arterioles. LXR has also been shown to interact with several components of the GPVI signaling pathway following treatment with GW3965, including Syk and PLCγ2, resulting in decreased phosphorylation and signaling (Spyridon et al. [@CR130]; Moraes et al. [@CR90]).

Glucocorticoid Receptor {#Sec11}
-----------------------

The glucocorticoid receptor (GR) is activated by glucocorticoid steroid hormones, a major class of anti-inflammatory hormones, and prednisolone a synthetic derivative of cortisol that has been used to understand the role of GR in the regulation of platelet function. Platelets preincubated with prednisolone prior to agonist stimulation show reduced aggregation and TxB~2~ release in response to both ADP and TxA~2~ mimetic U46619 which could be reversed following treatment with a GR antagonist mifepristone (Moraes et al. [@CR87]). However, the mechanism underlying negative regulation of platelet function by GR agonists is still poorly understood.

Negative Regulators of Small GTPases and Integrin α~IIb~β~3~ Activation {#Sec12}
=======================================================================

One of the key processes that underpin thrombus formation is the activation of the integrin α~IIb~β~3~. Activation of α~IIb~β~3~ results in a conformational change in the receptor that enables fibrinogen binding and aggregation, and also initiates outside in signaling which sustains platelet activation. Suppression of integrin α~IIb~β~3~ activation prevents inappropriate platelet aggregation and excessive thrombus formation that can cause vessel occlusion (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Negative regulators of small GTPases and integrin α~IIb~β~3~. RASA3 inhibits Rap1b, preventing signal transduction that enables integrin α~IIb~β~3~ activation until PI3K activation downstream of Gi-coupled P2Y12 inhibits RASA3. Wnt 3a activates the β-catenin signaling pathway that negatively regulates small GTPases including Rac1 and Rap1 that underpin integrin activation. The neuropilin-1-plexin A complex is activated by semaphorin 3A which also negatively regulates Rac1. JAM-A inhibits c-Src-dependent integrin α~IIb~β~3~ outside-in signaling through activation of Csk which negatively regulates c-Src. Stimulation with agonists causes dissociation of JAM-A from integrin α~IIb~β~3~, reducing Csk activity and enabling activation of c-Src mediated integrin α~IIb~β~3~ outside-in signaling. Semaphorin 3A is believed to activate the neuropilin-1 plexin A complex which inhibits Rac1 causing inhibition of integrin α~IIb~β~3~ activation

RASA3 {#Sec13}
-----

RASA3 has recently been identified as an important inhibitor of integrin α~IIb~β~3~ activation (Stefanini et al. [@CR135]) through the regulation of Rap1b which is a critical regulator of integrin function in platelets (Chrzanowska-Wodnicka et al. [@CR22]; Stefanini et al. [@CR134]). Rap1b is positively regulated by the Ca^2+^-sensing guanine exchange factor (GEF), CAlDAG-GEF1 (Crittenden et al. [@CR28]) and RASA3 provides opposing, negative regulation that maintains platelets in a quiescent state when at resting \[Ca^2+^\]~i~ (Stefanini et al. [@CR135]). RASA3 deficiency is embryonically lethal in mice but homozygous expression of a mutated form of RASA3 with impaired activity results in viable animals with platelet hyperreactivity that can be rescued by simultaneous deficiency of CALDAG-GEF1. However, integrin α~IIb~β~3~ activation in the double knockout mouse occurs independently of the ADP receptor P2Y12 and PI3K.

JAM-A {#Sec14}
-----

JAM-A is a transmembrane protein of the CTX family that is expressed on cell surface and has been identified in platelets. Mice deficient in JAM-A display increased aggregation to several platelet agonists, increased spreading on fibrinogen and clot retraction and increased thrombus formation indicating a role for JAM-A in the negative regulation of integrin α~IIb~β~3~ (Naik et al. [@CR98]). JAM-A is phosphorylated in resting platelets and associates with α~IIb~β~3~ (Naik et al. [@CR98]). JAM-A is proposed to keep the integrin inactive by binding C-terminal src kinase (Csk) via its SH2 domain which recruits it to the integrin. Recruitment of Csk ensures that c-Src, which is associated with the integrin, remains in an inactive state through phosphorylation of the inhibitory Y529 in c-Src's regulatory domain (Naik et al. [@CR99]). On platelet activation JAM-A is dephosphorylated, Csk dissociates enabling activation of c-Src and integrin α~IIb~β~3~ activation.

Studies using ApoE deficient mice that model high plasma cholesterol levels and atherosclerosis have highlighted the importance of the platelet inhibitory receptor JAM-A in the development of the disease state. A recent study has shown that platelet deficiency in the inhibitory receptor JAM-A in ApoE^−/−^ mice fed a high fat diet increases aortic plaque formation and recruitment of inflammatory cells, suggesting that platelet hyperreactivity such as that observed in JAM-A^−/−^ platelets can contribute to atherosclerotic plaque formation (Karshovska et al. [@CR62]).

ESAM {#Sec15}
----

ESAM, a transmembrane glycoprotein, like JAM-A is a member of the CTX family and is also suggested to be involved in the negative regulation of adhesion and integrin α~IIb~β~3~ outside-in signaling. In contrast to JAM-A, ESAM appears to negatively regulate integrin α~IIb~β~3~ and limit its activity following platelet activation. ESAM is contained in platelet alpha granules and is translocated to the cell surface on activation (Nasdala et al. [@CR100]). Mouse platelets deficient in ESAM show increased aggregation to GPCR agonists, inhibition of clot retraction, increased thrombus formation in vivo and reduced tail bleeding (Stalker et al. [@CR131]). The mechanism by which ESAM functions is currently unknown, although interaction via its PDZ domain with NHERF-1, a scaffold protein highlights possible interaction with and regulation of several proteins, including GPCRs (Hall et al. [@CR46]), G proteins and PLCβ (Rochdi et al. [@CR118]) and components of the cytoskeleton (Shenolikar et al. [@CR127]).

Wnt3a {#Sec16}
-----

Wnt3a is a glycoprotein that is released from endothelial cells (Goodwin et al. [@CR42]) and also from TRAP stimulated platelets, enabling platelets to self-regulate and limit activation (Steele et al. [@CR132]). Treatment of platelets with Wnt3a results in an inhibition of platelet adhesion and shape change, reduced dense granule secretion and reduced RhoA activation leading to diminished integrin α~IIb~β~3~ activation and aggregation. In platelets, Wnt3a is thought to exert its effects through activation of the canonical Wnt-β-catenin signaling pathway components that also appear to be present in platelets (Semenov et al. [@CR123]; MacDonald et al. [@CR74]; Huang and He [@CR54]). In other cell types β-catenin has been shown to play a role in the regulation of cell adhesion, where it is involved in supporting the interaction of cadherins to the cytoskeleton (Huang and He [@CR54]). Negative regulation of platelet activation via Wnt3a signaling is thought to occur through regulation of small GTPase activity, including Rap1, Cdc42, Rac1, RhoA (Steele et al. [@CR133]). It is thought that by favouring the GDP-bound state of Rap1 and Rho via the regulation of Rap1GAP and RhoA GTPase activity, whilst increasing levels of Cdc42 and Rac1 GTP levels, Wnt3a inhibits integrin α~IIb~β~3~ adhesion and spreading.

Neuropilin-1-Plexin A Complex {#Sec17}
-----------------------------

Semaphorin 3A exists as a soluble covalently bound homodimer and is secreted by vascular endothelial cells (Serini et al. [@CR126]). Semaphorin 3A negatively regulates platelet function through binding to the neuropilin-1-plexin A receptor complex which has been identified in platelets (Takahashi et al. [@CR137]; Tamagnone et al. [@CR139]; Kashiwagi et al. [@CR63]). Semaphorin 3A treatment inhibits platelet function, possibly through regulation of integrin α~IIb~β~3~ as activation of the integrin, aggregation and adhesion and spreading evoked by several platelet agonists are impaired. The exact mechanisms by which Semaphorin 3A inhibits platelet function have not been fully elucidated, although inhibition of the GTPase Rac1 appears to be a key regulatory step in the negative regulation of α~IIb~β~3~ and cytoskeletal rearrangements (Kashiwagi et al. [@CR63]).

Cyclic Nucleotide Signaling {#Sec18}
===========================

Cyclic nucleotides cAMP and cGMP are well-established inhibitors of platelet activation. Endothelium derived prostacyclin (PGI~2~) and nitric oxide (NO) activate the production of cAMP and cGMP, respectively, and play essential roles in keeping platelets in the resting state in the circulation. The regulation of platelets by these molecules is discussed in detail in Chapter X.

cAMP and Protein Kinase A {#Sec19}
-------------------------

PGI~2~ binds to and activates the prostaglandin receptor on the platelet surface (Dutta-Roy and Sinha [@CR32]), which then propagates inhibitory signaling through the activation of Gs subunits that activate adenylyl cyclase and stimulate the production of cAMP from ATP (Gorman et al. [@CR43]). cAMP activates cAMP dependent protein kinase A (PKA). Following platelet activation by agonists such as ADP and thrombin, adenylyl cyclase activity is inhibited and cAMP levels reduced through Gi signaling (Jantzen et al. [@CR56]; Yang et al. [@CR159]). PKA phosphorylates multiple target proteins that maintain platelets in an inactive resting state by limiting platelet activation. Several substrates of PKA have been well characterised and are linked to the negative regulation of platelets, including VASP which is involved in cytoskeletal rearrangements (Waldmann et al. [@CR153]; Butt et al. [@CR15]), inhibition of Rap1b a key regulator of integrin α~IIb~β~3~ affinity (Schultess et al. [@CR122]; Miura et al. [@CR83]), inositol trisphosphate receptor (IP~3~R) which is involved in Ca^2+^ regulation (Cavallini et al. [@CR18]) and the thromboxane A2 receptor (Reid and Kinsella [@CR115]). Other targets also include Gα13 (Manganello et al. [@CR75]), GPIbβ (Wardell et al. [@CR154]) and CALDAG-GEFI (Schultess et al. [@CR122])

Recent studies have identified a cAMP independent mechanism of PKA activation following stimulation of platelets by thrombin or collagen (Gambaryan et al. [@CR39]). In resting platelets a population of platelet PKA appears to be associated with NFkB-IkBα. Following stimulation by collagen or thrombin the catalytic subunit of PKA dissociates from NFkB-IkBα and is activated, enabling phosphorylation and activation of its substrates. This identifies an inhibitory feedback mechanism that prevents excessive platelet activation in response to stimuli (Gambaryan et al. [@CR39]).

Regulation of cGMP and PKG by Platelet-Derived NO {#Sec20}
-------------------------------------------------

The cyclic nucleotide cGMP is a key negative regulator of platelet activation that inhibits platelets to keep them in the resting state in the healthy vasculature (Smolenski [@CR129]). Endothelial release of nitric oxide (NO) keeps platelets inactive by regulating their intracellular levels of cGMP (Mellion et al. [@CR80]; Radomski et al. [@CR111]). Following the synthesis and release of NO from the healthy endothelium, NO crosses the platelet plasma membrane and binds to and activates, soluble guanyl cyclase (sGC), leading to the increased production of cGMP from GTP and activation of protein kinase G (PKG). Levels of cGMP are controlled by the phosphodiesterase, PDE5A which is present in platelets (Haslam et al. [@CR51]). Platelets deficient in PKG are insensitive to cGMP-mediated inhibition of intracellular Ca^2+^ release (Eigenthaler et al. [@CR33]) and PKG knockout mice have a prothrombotic phenotype and exhibit increased intravascular adhesion and aggregation following ischaemia (Massberg et al. [@CR76]).

Platelets are now also considered to be a source of NO. The mechanism by which platelets synthesise NO and whether or not it is of physiological importance is, however, still an area of contention. Although NO itself is an established negative regulator of platelet function, the vascular endothelium has traditionally been considered the dominant source of NO within blood vessels. Platelets have been reported to express two nitric oxide synthase (NOS) isoforms, iNOS and eNOS but generate less NO than endothelial cells (Radomski et al. [@CR113]) and the presence of eNOS is contentious (Gambaryan et al. [@CR38]). Studies into the effects of platelet-derived NO on platelet function using iNOS/eNOS knockout mice have suggested that eNOS is not a major regulator of platelet function (Gambaryan et al. [@CR38]; Tymvios et al. [@CR147]). There is evidence that platelets can produce NO from nitrate although further research is needed to understand the mechanism (Apostoli et al. [@CR7]). Platelet NO production is inducible and is mediated by Ca^2+^ elevation (Radomski et al. [@CR113]) and is therefore stimulated by many platelet agonists such as ADP and arachidonic acid. However, the question of whether platelet-derived NO can inhibit platelet aggregation is a source of debate (Gkaliagkousi et al. [@CR41]) with some reports describing platelet-derived NO-mediated inhibition (Radomski et al. [@CR112], [@CR113]) and others reporting no effect (Thomas et al. [@CR144]; Thompson et al. [@CR146]). More recent studies have provided further evidence for the presence of functional eNOS in platelets by measuring NO production in single platelets under flow (Cozzi et al. [@CR27]) and also highlighted the anti-thrombotic potential of drugs that modulate platelet eNOS activity (Momi et al. [@CR85]).

Defects in cAMP/cGMP signaling pathways have the potential to contribute to platelet hyperreactivity in cardiovascular disease including ischemic heart disease, heart failure and diabetes where the reduced sensitivity of platelets to the inhibitory effects of NO contributes to platelet hyperreactivity (Chirkov and Horowitz [@CR21]). Platelets from patients with type 2 diabetes mellitus and insulin insensitivity, for example, have reduced sensitivity to NO and prostacyclin and consequently higher platelet reactivity. Additionally a number of individuals with genetic abnormalities in prostacyclin signaling have reduced cAMP levels, resulting in hyper-reactive platelets and a prothrombotic state, and defects in sGC function are linked to an increase prevalence of ischemic heart disease, heart failure and diabetes (van Geet et al. [@CR149]). In contrast patients with hypersensitivity to prostacyclin signaling, as a result of increased activity of Gs proteins show an increased risk of bleeding which is attributed to increased cAMP levels and an increased inhibition of platelet function (van Geet et al. [@CR149]). It is also suggested that in patients with obesity in addition to defects in sGC function, cAMP synthesis may also be altered and defects in downstream effectors of cAMP and cGMP signaling may contribute to platelet hyperreactivity (Russo et al. [@CR119]).

Other Mechanisms of Platelet Inhibition {#Sec21}
=======================================

Phosphatases {#Sec22}
------------

Protein modification by phosphorylation is a key mechanism of signal transduction in platelets. Phosphorylation is a reversible post-translational modification that enables regulation of signal transduction and platelet function by phosphatase dependent dephosphorylation of key signaling proteins. Phosphatases are key mediators of several negative signaling pathways in platelets such as those exhibited by the ITIM containing receptors. Protein tyrosine phosphatases such as SHP1 and SHP2, SHIP1 and SHIP2, PP2, PTEN and TULA2 have well-established roles in the negative regulation of platelet signaling, in general negatively regulating receptor proximal signaling events leading to reduced mobilisation of Ca^2+^, granule secretion and integrin activation (Senis [@CR124]). SHP2 is well-established for its roles in the negative regulation of platelet signaling events downstream of the majority of platelet agonists, including GPVI and GPCRs (Ma et al. [@CR72]; Jackson et al. [@CR55]). These observations are supported by studies using mouse platelets deficient in SHP2 which show enhanced activation to fibrinogen (Mazharian et al. [@CR79]). The histidine phosphatase TULA2 dephosphorylates and inactivates Syk preventing further downstream signaling (Thomas et al. [@CR145]). TULA2 deficient mice platelets show increased hyperreactivity to GPVI agonists, and also increased thrombus formation and reduced bleeding times. The phosphoinositide phosphatases SHIP1 and PTEN are involved in the regulation of PI3K function through alteration of the phosphoinositol cycle (Laurent et al. [@CR67]). PTEN-deficient platelets which show hyper-responsiveness to collagen exhibit increased PI3K activity and show reduced bleeding times in vivo. Finally the serine/threonine kinase phosphatase PP2A is involved in the negative regulation of integrin α~IIb~β~3~ function and signaling (Pradhan et al. [@CR108]; Gushiken et al. [@CR45]). PP2A mediates dephosphorylation of PKCζ and PTP-1B which reduces Src phosphorylation and activation (Mayanglambam et al. [@CR77]; Pradhan et al. [@CR108]; Gushiken et al. [@CR45]). It is important to note, however, that whilst several phosphatases are associated with negative regulation of platelet function, many positive regulatory functions for phosphatases have been identified in platelets (Senis [@CR124]).

Receptor Desensitisation {#Sec23}
------------------------

Platelets can regulate and limit their responsiveness to platelet agonists, through desensitisation of their receptors following agonist stimulation. ADP, for example, is a critical secondary mediator of platelet signaling, yet despite this it has been shown that platelets desensitise following continued exposure to ADP (Mundell et al. [@CR94]; Hardy et al. [@CR48]; Cunningham et al. [@CR29]). This diminished response is attributed to desensitisation of both the P2Y1 and P2Y12 receptors via agonist mediated internalisation of each receptor. Studies using both platelets and 1321N1 cells have identified that the P2Y1 and P2Y12 receptors are desensitised by different mechanisms following platelet agonist stimulation. Desensitisation of the P2Y1 receptor is mediated by both classical and novel isoforms of protein kinase C (PKC), whilst P2Y12 desensitisation is mediated by G protein coupled receptor kinase and the novel isoforms of PKC (Hardy et al. [@CR48]).

PKC Isoforms {#Sec24}
------------

Protein kinase C (PKC), a family of serine/threonine kinases regulates many aspects of platelet signaling. The different isoforms of PKC are classified into three different subtypes classical, novel and atypical isoforms, according to their structure and mechanism of regulation. Several isoforms have been identified in human platelets although expression of some isoforms is controversial (Newton [@CR103]; Mellor and Parker [@CR81]; Murugappan et al. [@CR95]; Buensuceso et al. [@CR14]; Hall et al. [@CR47]; Pears et al. [@CR106]; Konopatskaya et al. [@CR66]; Bynagari et al. [@CR16]; Nagy et al. [@CR97]; Harper and Poole [@CR50]). Historically the PKC family were considered to play an overall positive role in the regulation of platelet activity, as broad spectrum PKC inhibitors were shown to inhibit granule secretion, TxA~2~ synthesis, integrin activation, aggregation and thrombus formation (Harper and Poole [@CR50]). However, negative regulatory roles have subsequently also been identified for the PKC family. Studies using broad spectrum inhibitors have also identified negative roles in the regulation of receptor desensitisation (see section on receptor desensitisation) and Ca^2+^ release, and studies using isoform specific deficient mice have identified negative regulatory roles for the novel isoforms PKCδ and PKCθ (Harper and Poole [@CR50]).

Transgenic mice deficient in PKCδ have identified a negative regulatory role for PKCδ in the regulation of integrin α~IIb~β~3~ outside-in signaling and filopodia formation on fibrinogen due to an interaction between PKCδ and VASP (Pula et al. [@CR109]). PKCδ has also been shown to negatively regulate GPVI-induced platelet responses, as platelets from PKCδ deficient mice have enhanced aggregation and dense granule secretion in comparison to WT controls. This was also confirmed in human platelets using a cell permeable peptide that is designed to block the interaction of PKCδ and δ(V1-1)-TAT (Chari et al. [@CR19]). Contrasting reports, however, also exist as other groups found no abnormality in GPVI-dependent dense granule secretion in PKCδ^−/−^ platelets (Pula et al. [@CR109]). PKCδ deficient platelets generate larger thrombi when measured in vitro but not when measured in vivo (Gilio et al. [@CR40]; Chari et al. [@CR19]). The overall role of PKCδ has therefore been difficult to define, possibly as a consequence of diverse positive and negative regulatory roles played by this PKC isoform.

Studies that have utilised PKCθ isoform-specific inhibitors have identified negative roles for PKCθ in several processes in GPVI-induced platelet activation, including aggregation, α-granule secretion, α~IIb~β~3~ activation and changes in intracellular Ca^2+^ levels, as all were increased following treatment of platelets with the inhibitor. Studies that have utilised PKCθ deficient mice have generated conflicting reports of both positive and negative roles in the regulation of platelet activation (Hall et al. [@CR47]; Nagy et al. [@CR97]; Harper and Poole [@CR49], [@CR50]; Cohen et al. [@CR25]; Unsworth et al. [@CR148]; Gilio et al. [@CR40]). These differences have been attributed to different experimental conditions whereby PKCθ may have a negative role following exposure to low agonist concentrations, and a positive role following exposure to higher concentrations of platelet agonists (Hall et al. [@CR47]; Nagy et al. [@CR97]; Cohen et al. [@CR25]).

Conclusion {#Sec25}
==========

Platelet-derived mediators of negative regulation all function to limit or restrict platelet activation, yet are mechanistically diverse and affect pathways involved in many different processes (Fig. [4](#Fig4){ref-type="fig"}). While many negative regulators have been identified, many of the processes that they regulate to achieve platelet inhibition are not yet fully characterised. However, it is becoming increasingly clear that negative regulatory mechanisms rival the complexity of the positive regulators of platelet activation. The key challenge in the field of inhibitory platelet signaling will be to establish the physiological and pathological importance of these proteins, their potential as drug targets and their role in determining disease risk.Fig. 4Platelet-derived inhibitors of platelet function. Well-characterised activatory pathways (*black*) are regulated by multiple inhibitory pathways that regulate platelet responses to support their role in hemostasis. Receptors that signal through ITIMs (*blue*) recruit SHP1/2 and SHIP1/2 in close proximity to ITAM receptors where they dephosphorylate components of activation pathways, inactivating them to provide negative regulation. Small GTPases regulate several important process in platelets such as granule secretion and integrin α~IIb~β~3~ activation and so inhibitors of small GTPases (*yellow*) such as RASA3 and Wnt3a/β-catenin provide negative regulation for these key events. PKA and PKG are inhibitory kinases that are regulated by cyclic nucleotides (*green*), although these pathways are primarily regulated by non-platelet-derived inhibitors they are also potentially regulated by platelet-derived NO and non-cAMP dependent PKA activation. Other negative regulators (*purple*) such as phosphatases and kinases that regulate receptor desensitisation do not easily fit into discrete categories and mediate negative feedback via diverse mechanisms

Take Home Messages {#FPar1}
------------------

Platelet activation is triggered by stimuli that arise within the circulationActivated platelets initiate their own positive feedback mechanisms that support thrombus growthPlatelets also generate negative feedback signals that can limit thrombus developmentThe mechanisms of negative regulators are diverse and many have not yet been fully characterisedNegative regulatory mechanisms may be as important as positive regulators to understand disease risk and discover new drug targets and therapies
